<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326910</url>
  </required_header>
  <id_info>
    <org_study_id>COOADM3002</org_study_id>
    <secondary_id>HTR 11-130435-111</secondary_id>
    <nct_id>NCT01326910</nct_id>
  </id_info>
  <brief_title>Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema</brief_title>
  <official_title>A Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of an Over-the-Counter Cream in the Management of Mild to Moderate Atopic Dermatitis in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Consumer Products Company Division of Johnson &amp; Johnson Consumer Companies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This three week study will be conducted to determine the safety and efficacy of an
      over-the-counter (OTC) cream in children with mild to moderate atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this trial is to evaluate the efficacy and safety of an OTC colloidal
      oatmeal skin protectant cream in children with mild to moderate AD in comparison to that of
      EpiCeramÂ®
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema Area and Severity Index (EASI)</measure>
    <time_frame>3 weeks</time_frame>
    <description>A regional body surface area tabulation based on severity ranging from 0 (none) to 3 (severe), and severity of signs of disease, then multiplied by body area with final calculation ranging from 0-72</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interim Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Week 2</time_frame>
    <description>Number of subjects improved at Week 2 compared to Baseline in EASI. Improved is defined as post baseline EASI score smaller than baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Itch</measure>
    <time_frame>through Week 3</time_frame>
    <description>Subject's or caregiver's assessment of itch, on a 10-cm Visual Analogue Scale (VAS), where 0-no itch, 10-worst itch imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Atopic Dermatitis Assessment (IGADA)</measure>
    <time_frame>through Week 3</time_frame>
    <description>An assessment of Atopic Dermatitis based on a 4 point scale where 0 (none) and 3 (severe) are used to describe signs and symptoms in 4 designated body regions. Based on the presence or absence of the total number of signs and symptoms, the final rating will be 0-clear, 1-almost clear, 2-mild, 3-moderate, 4-severe, or 5-very severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>19306-127</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Topical cream applied twice daily (or as needed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>19306-137</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Marketed Topical cream applied twice daily (or as needed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colloidal Oatmeal</intervention_name>
    <description>Topical cream applied twice daily (or as needed)</description>
    <arm_group_label>19306-127</arm_group_label>
    <other_name>Not yet marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Topical Cream</intervention_name>
    <description>Topical cream applied twice daily (or as needed)</description>
    <arm_group_label>19306-137</arm_group_label>
    <other_name>EpiCeram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children ages 6 mo- 18 years

          -  Any ethnicity

          -  Diagnosed with atopic dermatitis (AD) per Hanifin-Rajka criteria

          -  Mild to moderate atopic dermatitis per Rajka-Langeland severity index

          -  Willing to use only provided cream and body wash for duration of study

        Exclusion Criteria:

          -  Known sensitivity to investigational products

          -  Pregnant or breastfeeding

          -  Severe AD per Rajka-Langeland severity index

          -  AD requiring class I (super potent) or class II or III (potent) topical steroids

          -  Requires greater than 2.0 g inhaled or intranasal corticosteroids

          -  Other skin conditions which may interfere with the scoring of AD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qing Li, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Consumer and Personal Products Worldwide</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hilltop Research</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hilltop Research</name>
      <address>
        <city>Miamiville</city>
        <state>Ohio</state>
        <zip>45147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2011</study_first_posted>
  <results_first_submitted>June 27, 2012</results_first_submitted>
  <results_first_submitted_qc>June 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2012</results_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>19306-127</title>
          <description>Experimental Topical cream applied twice daily (or as needed)</description>
        </group>
        <group group_id="P2">
          <title>19306-137</title>
          <description>Marketed Topical cream applied twice daily (or as needed)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>19306-127</title>
          <description>Experimental Topical cream applied twice daily (or as needed)</description>
        </group>
        <group group_id="B2">
          <title>19306-137</title>
          <description>Marketed Topical cream applied twice daily (or as needed)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="3.26"/>
                    <measurement group_id="B2" value="9.3" spread="4.26"/>
                    <measurement group_id="B3" value="8.1" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Eczema Area and Severity Index (EASI)</title>
        <description>A regional body surface area tabulation based on severity ranging from 0 (none) to 3 (severe), and severity of signs of disease, then multiplied by body area with final calculation ranging from 0-72</description>
        <time_frame>3 weeks</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>19306-127</title>
            <description>Experimental Topical cream applied twice daily (or as needed)</description>
          </group>
          <group group_id="O2">
            <title>19306-137</title>
            <description>Marketed Topical cream applied twice daily (or as needed)</description>
          </group>
        </group_list>
        <measure>
          <title>Eczema Area and Severity Index (EASI)</title>
          <description>A regional body surface area tabulation based on severity ranging from 0 (none) to 3 (severe), and severity of signs of disease, then multiplied by body area with final calculation ranging from 0-72</description>
          <population>Intention to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.014" spread="1.9473"/>
                    <measurement group_id="O2" value="3.359" spread="3.6925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.286" spread="1.0137"/>
                    <measurement group_id="O2" value="1.621" spread="1.9275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.310" spread="2.0153"/>
                    <measurement group_id="O2" value="1.298" spread="1.5811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.154" spread="1.1570"/>
                    <measurement group_id="O2" value="1.064" spread="1.1320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interim Eczema Area and Severity Index (EASI)</title>
        <description>Number of subjects improved at Week 2 compared to Baseline in EASI. Improved is defined as post baseline EASI score smaller than baseline score.</description>
        <time_frame>Week 2</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>19306-127</title>
            <description>Experimental Topical cream applied twice daily (or as needed)</description>
          </group>
          <group group_id="O2">
            <title>19306-137</title>
            <description>Marketed Topical cream applied twice daily (or as needed)</description>
          </group>
        </group_list>
        <measure>
          <title>Interim Eczema Area and Severity Index (EASI)</title>
          <description>Number of subjects improved at Week 2 compared to Baseline in EASI. Improved is defined as post baseline EASI score smaller than baseline score.</description>
          <population>Intention to Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" spread="1.8789"/>
                    <measurement group_id="O2" value="38" spread="2.8447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Itch</title>
        <description>Subjectâs or caregiverâs assessment of itch, on a 10-cm Visual Analogue Scale (VAS), where 0-no itch, 10-worst itch imaginable</description>
        <time_frame>through Week 3</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>19306-127</title>
            <description>Experimental Topical cream applied twice daily (or as needed)</description>
          </group>
          <group group_id="O2">
            <title>19306-137</title>
            <description>Marketed Topical cream applied twice daily (or as needed)</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Itch</title>
          <description>Subjectâs or caregiverâs assessment of itch, on a 10-cm Visual Analogue Scale (VAS), where 0-no itch, 10-worst itch imaginable</description>
          <population>Intention to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.557" spread="2.2526"/>
                    <measurement group_id="O2" value="1.208" spread="2.4939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.840" spread="2.2876"/>
                    <measurement group_id="O2" value="1.537" spread="2.2051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.199" spread="2.4595"/>
                    <measurement group_id="O2" value="1.480" spread="2.1464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.972" spread="2.7890"/>
                    <measurement group_id="O2" value="1.685" spread="2.5902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator's Global Atopic Dermatitis Assessment (IGADA)</title>
        <description>An assessment of Atopic Dermatitis based on a 4 point scale where 0 (none) and 3 (severe) are used to describe signs and symptoms in 4 designated body regions. Based on the presence or absence of the total number of signs and symptoms, the final rating will be 0-clear, 1-almost clear, 2-mild, 3-moderate, 4-severe, or 5-very severe.</description>
        <time_frame>through Week 3</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>19306-127</title>
            <description>Experimental Topical cream applied twice daily (or as needed)</description>
          </group>
          <group group_id="O2">
            <title>19306-137</title>
            <description>Marketed Topical cream applied twice daily (or as needed)</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Global Atopic Dermatitis Assessment (IGADA)</title>
          <description>An assessment of Atopic Dermatitis based on a 4 point scale where 0 (none) and 3 (severe) are used to describe signs and symptoms in 4 designated body regions. Based on the presence or absence of the total number of signs and symptoms, the final rating will be 0-clear, 1-almost clear, 2-mild, 3-moderate, 4-severe, or 5-very severe.</description>
          <population>Intention to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.159" spread="0.6078"/>
                    <measurement group_id="O2" value="2.182" spread="0.6567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.690" spread="0.6803"/>
                    <measurement group_id="O2" value="1.667" spread="0.7861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.585" spread="0.7062"/>
                    <measurement group_id="O2" value="1.548" spread="0.8025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.585" spread="0.8055"/>
                    <measurement group_id="O2" value="1.381" spread="0.7949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three Weeks plus 30 days for Serious Adverse Events</time_frame>
      <group_list>
        <group group_id="E1">
          <title>19306-127</title>
          <description>Experimental Topical cream applied twice daily (or as needed)</description>
        </group>
        <group group_id="E2">
          <title>19306-137</title>
          <description>Marketed Topical cream applied twice daily (or as needed)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The trial was conducted as work made for hire, and disclosure of results by the investigator is prohibited without the prior written consent of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joyce Hauze, Sr. Specialist Clinical Quality Systems and Process</name_or_title>
      <organization>Johnson &amp; Johnson Consumer and Personal Products Worldwide</organization>
      <phone>928-277-0715</phone>
      <email>jhauze@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

